Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: GlobeNewswire
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on February 2, 2026 to two new employees under Bicara’s 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate, non-qualified stock options to purchase 158,900 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $16.76 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on February 2, 2026. One-fourth of the options vest on the first anniversary of the employee’s applicable start date, with the remaining options vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued service with the company through each applicable vesting date. All of the above-described awards were granted
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- Bicara Therapeutics (NASDAQ:BCAX) is now covered by analysts at Citizens Jmp. They set a "market perform" rating and a $31.00 price target on the stock.MarketBeat
- Bicara Therapeutics (NASDAQ:BCAX) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.MarketBeat
- Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at BTIG Research.MarketBeat
- Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
BCAX
Earnings
- 11/10/25 - Miss
BCAX
Sec Filings
- 2/5/26 - Form SCHEDULE
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- BCAX's page on the SEC website